GSK plc (GSK), Monday confirmed that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational ileal bile acid transporter inhibitor, to treat cholestatic pruritus in primary biliary cholangitis. The submission follows FDA acceptance earlier this month. The MAA is supported by data from the Phase III GLISTEN trial, in which linerixibat delivered rapid, significant and sustained reductions in itch severity and itch-related sleep interference versus placebo, with a safety profile consistent with previous studies. Cholestatic pruritus affects up to 90 percent of PBC patients and can severely impair quality of life. Linerixibat currently holds orphan drug designation in the US and EU and remains under review for approval globally. GSK is currently trading at $37.99, down $0.08 or 0.22 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.